

## Poly Medicure Limited

Regd. Office : 232-B, 3<sup>rd</sup> Floor, Okhla Industrial Estate,  
Phase-III, New Delhi - 110020 (INDIA)  
T: +91-11-33550700, 47317000, F: +91-11-26321894, 26321839  
E: info@polymedicure.com W: polymedicure.com  
CIN: L 40300DL1995PLC066923



Date: 24<sup>th</sup> May, 2022

**Scrip Code: - 531768**

**The Manager,**  
**BSE Limited,**  
Department of Corporate Services,  
Phirozee Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400001.

**Scrip Code:- POLYMED**

**The Manager**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Plot No. C/1-Block-G  
Bandra Kurla Complex, Bandra(E),  
Mumbai-400051.

**Subject: Compliance of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation for FY 2021-22**

**Dear Sir/Madam,**

Please find enclosed the Investor Presentation covering the performance highlights of the Company for FY 2021-22.

We have also uploaded the presentation on the Website of the Company at [www.polymedicure.com](http://www.polymedicure.com)

We request you to take the above on record and the same be treated as the necessary compliance under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking You,

Yours Sincerely

For Poly Medicure Limited

Avinash Chandra  
Company Secretary



# Investors Presentation

May 2022

**25**  
YEARS  
Touching Lives with Care

# DISCLAIMER

This presentation has been prepared by Poly Medicure Limited (the “Company”) solely for your information and may not be distributed, reproduced, or redistributed or passed on directly or indirectly to any other person, whether within or outside your organization or firm, or published in whole or in part, for any purpose by recipients directly or indirectly to any other person. By accessing this presentation, you agree to be bound by the following restrictions and to maintain absolute confidentiality regarding the information disclosed in these materials. The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any persons of such change or changes. This presentation and its contents are confidential and may not be copied, published, reproduced or disseminated in any manner.

This presentation may contain certain forward looking statements based on the currently held beliefs and assumptions of the management of the Company which are expressed in good faith and in their opinion, reasonable. These statements include descriptions regarding the intent, belief or current expectations of the Company or its directors and officers with respect to the results of operations and financial condition of the Company. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in such forward-looking statements as a result of various factors and assumptions which the Company believes to be reasonable in light of its operating experience in recent years. Many factors could cause the actual results, performances, or achievements of the Company to be materially different from any future results, performances, or achievements. Significant factors that could make a difference to the Company’s operations include, but are not reasonable to, domestic and international economic conditions, changes in government regulations, tax regime and other statutes. The Company does not undertake to revise any forward-looking statement that may be made from time to time by or on behalf of the Company.

This presentation contains certain supplemental measures of performance and liquidity that are not required by or presented in accordance with Indian GAAP, and should not be considered an alternative to profit, operating revenue or any other performance measures derived in accordance with Indian GAAP or an alternative to cash flow from operations as a measure of liquidity of the Company.

In no event shall the Company be responsible to any person or entity for any loss or damage, whether direct, indirect, incidental, consequential or otherwise, arising out of access or use or dissemination of information contained in this presentation, including, but not limited to, loss of profits. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein and, accordingly, none of the Company, its advisors and representative and any of its or their affiliates, officers, directors, employees or agents, and anyone acting on behalf of such persons accepts any responsibility or liability whatsoever, in negligence or otherwise, arising directly or indirectly from this presentation or its contents or otherwise arising in connection therewith.

You must make your own assessment of the relevance, accuracy and adequacy of the information contained in this presentation and must make such independent analysis as you may consider necessary or appropriate for such purpose. Any opinions expressed in this presentation are subject to change without notice and past performance is not indicative of future results. By attending this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company’s business.

This presentation and its contents are not and should not be construed as a prospectus or an offer document, including as defined under the Companies Act, 2013, to the extent notified and in force) or an offer document under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended. This presentation is not for publication or distribution or release in any country where such distribution may lead to a breach of any law or regulatory requirement. The information contained herein does not constitute or form part of an offer, or solicitation of an offer to purchase or subscribe, for securities for sale. The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. None of the Company’s securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration therefrom.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Delhi, and no other courts, shall have jurisdiction over the same.





# Content

Our Journey

Board of Directors & Management

Corporate Structure

Polymed's Unique Position

Five Year Vision

Customer Stickiness, Sustainable Business

Manufacturing

Key Financials and Ratios

New Product launches


Corporate Communication

Way Forward, Capex Update

Awards and recognition



# OUR JOURNEY.....MILESTONE ACHIEVEMENTS



Established in 1997, POLYMED is a key player in the Indian Medical Devices Industry

# ACROSS THE WORLD, WE SERVE PEOPLE IN OVER 120+ COUNTRIES



- 9 Manufacturing Plants\*  
(\*2 under construction)
- 1 R&D Center

UNIQUELY POSITIONED TO PROVIDE VALUE TO OUR CUSTOMERS



# BOARD OF DIRECTORS & MANAGEMENT



**Mr. Devendra Raj Mehta**  
(Chairman,  
Non Executive Independent Director)



**Mr. Himanshu Baid**  
(Managing Director)



**Mr. Rishi Baid**  
(Joint Managing Director)



**Mr. Jugal Kishore Baid**  
(Non Executive Director)



**Mrs. Mukulika Baid**  
(Non Executive Director)



**Dr. Shailendra Raj Mehta**  
(Non Executive Independent Director)



**Mr. Prakash Chand Surana**  
(Non Executive Independent Director)



**Dr. Sandeep Bhargava**  
(Non Executive  
Independent Director)



**Mr. Alessandro Balboni**  
(Non Executive  
Non Independent Director)



**Mr. Amit Khosla**  
(Non Executive Independent  
Director)



**Ms. Sonal Mattoo**  
(Non Executive Independent  
Director)



**Strong Management with experience in Innovation, Product Development and Manufacturing**



# CORPORATE STRUCTURE



## POLYMED GROUP

INDIA

**Poly Medicure Ltd  
Holding Co.**

**Plan 1 Health India Pvt. Ltd.**  
Wholly owned Subsidiary (100%)

OVERSEAS

**Poly Medicure  
(Laiyang) Co. Ltd.  
China**  
Wholly owned  
Subsidiary (100%)

**Poly Medicure BV-  
Netherlands**  
Wholly owned  
Subsidiary  
(100%)

**Ultra for Medical  
Products Co.  
(UMIC) – Egypt**  
Associate (23%)

**Plan 1 Health Italy**  
Step Down Subsidiary (100%)


**PolyHealth Medical Inc. USA**  
Step Down Subsidiary (100%)



# POLYMED'S UNIQUE POSITION

## EMINENCE IN FLUID MANAGEMENT DISPOSABLES AND PROCEDURAL MEDICAL DEVICES

### COMPREHENSIVE PRODUCT RANGE



### INNOVATION, AN INTEGRAL PART OF POLYMED STORY

## Amongst the Top 3

I.V. Cannula Manufacturer in the world

In India

# 1st

Indigenous Dialyzer Manufacturer

In India

# 275+

Sales Associates

# 6500+

Hospitals Reach

In India

# 30+

Clinical Specialists

# 50,000+

HCP's Reach

## Largest Exporter

Largest exporter of Consumable Medical Devices from India **10 years** in a row.



Portfolio of more than **160 Medical Devices**

**25 Years of manufacturing excellence**

# 2020-2025 VISION

## TRANSFORM FROM A PRODUCT COMPANY TO A SOLUTION PROVIDER ORGANIZATION

### Started in 1997

Commencement of Manufacturing Operation

### 2002-2009

Product and facility expansion

### 2011-2019

New R&D Center  
Acq of Plan 1 Health  
New Manufacturing Plants



### 2020-2021

Focus on commercial launch of current product pipeline

Invest in development of infection reduction and fluid management and accelerate time to market

Upscale R&D and Operations

### 2022-2025

Launch differentiated new products in premium markets and geographies

Accelerate growth in developed countries

### 2026 and beyond

Globally recognized solution provider of infection reduction technologies and fluid management products

**TODAY**



**Preferred Supplier**



Supplier of 1<sup>st</sup> Choice



**Solutions Partner**



Driving Delivery of Health Care




Value Based Supplier



# STICKINESS IN CUSTOMER BASE & SUSTAINABLE BUSINESS


LEVERAGE OUR (CUSTOMER) INSTALLED BASE AND DISTRIBUTOR NETWORK TO LAUNCH NEW PRODUCTS

### Polymed Sales By Geography




Export India

### Polymed Sales By Product Category



Infusion Therapy Surgery & Wound Drainage Renal  
Blood Transfusion Anaesthesia & Respiratory Other

### Polymed Brand and OEM Private Label Sales



PolyMed Brand OEM



# MANUFACTURING ACROSS FOUR COUNTRIES

(INDIA, ITALY, EGYPT, CHINA)



1<sup>st</sup> Medical Device Company from India to have overseas plants.

Over 275+ Moulding Machines & 900+ Injection Molds

More than 200+ automatic assembly machines with vision control systems.

30+ Robots used in manufacturing.



Faridabad Plant, India



Haridwar Plant, India



IMT Faridabad India



Faridabad Plant, India



Jaipur Plant, India



R & D Center, FBD, India



Laiyang-qingdao, China



Assuit, Egypt



Amaro, Italy






# OUR STRENGTH: Consistent all-round growth (Standalone)



## REVENUE (₹ Crs.)




■ FY 2020 ■ FY 2021 ■ FY 2022

Year	Revenue
FY 2020	646.16
FY 2021	747.38
FY 2022	879.36



## EBIDTA (₹ Crs.)




■ FY 2020 ■ FY 2021 ■ FY 2022

Year	EBIDTA	%
FY 2020	160.14	24.78%
FY 2021	208.30	27.87%
FY 2022	212.13	24.12%



## PBT (₹ Crs.)




■ FY 2020 ■ FY 2021 ■ FY 2022

Year	PBT	%
FY 2020	121.78	18.85%
FY 2021	173.36	23.20%
FY 2022	194.72	22.14%



## PAT (₹ Crs.)




■ FY 2020 ■ FY 2021 ■ FY 2022

Year	PAT	%
FY 2020	92.38	14.30%
FY 2021	129.50	17.33%
FY 2022	146.02	16.60%




# CREATING VALUE FOR SHAREHOLDERS

## Increasing Shareholders Base



Date	No of Shareholders
31-03-2020	8,574
31-03-2021	21,531
31-03-2022	33,831

## Creating Value for Shareholders




Date	Market Cap in INR (Cr)
31-03-2020	2,056.36
31-03-2021	7,884.74
31-03-2022	9,105.74




# RATIO'S


### Interest Coverage




### Debt Service Coverage



### ROCE




### ROE




\* Increase in Share Capital due to QIP in Feb 2021



# PERFORMANCE STANDALONE/CONSOLIDATED



Year	Revenue	EBIDTA	PBT	PAT
FY 2020	646.16	160.14	121.78	92.38
FY 2021	747.38	208.30	173.36	129.50
FY 2022	879.36	212.13	194.72	146.02




\* All subsidiaries





# NEW PRODUCT LAUNCHES - FY 22-23



Arterial blood collection syringe



ECG- Electrode



PICC Line



Polyguard +



Labside filter  
(Blood Bank Side filter )



Bedside Filter



Hubber Needle  
(Oncology)



Diagnostic Kits



Concentrate

Disinfectant



Midflux PP & PC, and High Flux PP & pc Dialyzer –  
1.4, 1.6, 1.8



Dialyzer Reprocessor



Polyfit Range

# PRODUCTION LINKED INCENTIVE SCHEME (RENAL CARE)



- Polymed got approval under Renal Care Segment for following products
  - ✓ Dialyzer
  - ✓ Dialysis Machine
  - ✓ Peritoneal Dialysis Kit
  - ✓ Bloodline
  - ✓ Fistula
  - ✓ Transducer Protector
- Greenfield projects defined under the guidelines to be operational at IMT Plant
- Committed Investment of 70 Crs under the scheme from FY 2022-28
- 12 Crs of Investment done upto Mar-22 under the scheme

# PRODUCTION LINKED INCENTIVE SCHEME (IN VITRO DIAGNOSTIC)



- Polymed got approval under In Vitro Diagnostic Medical devices for following products
- New range of Molecular Chemicals, reagents and diagnostic kits to be added.
- Greenfield projects defined under the guidelines to be operational at IMT Plant
- Committed Investment of 50 Crs under the scheme from FY 2022-28
- 11 Crs of Investment done upto Mar-22 under the scheme




# CORPORATE COMMUNICATION

Media | Industry Events | Webinars | Social Media | Clinical Engagements | Conferences



1 lac + followers on social media  
250 posts pushed last year



**CII Annual Summit 2022**



# CORPORATE COMMUNICATION

Media | Industry Events | Webinars | Social Media | Clinical Engagements | Conferences



Arab Health  ARAB HEALTH 2022, DUBAI



 MEDICA 2021, GERMANY



# WAY FORWARD

## Vascular Access

- Relationship building with corporate chain of hospitals
- Expand Dealer network

01

## Renal

- Introduce Indigenous Dialysis Machine
- Expand Dialyzer range

02

## Research & Development

- Increase R&D investments
- Shorter lead time for commercialization

03



## International Strategy

- Transition to MDR
- Improve Brand visibility in International markets

04

## Promote Infection Prevention and Safety

- Targeted Clinical engagement

05

## Operational Excellence

- Build sustainability
- Adopt best ESG standards
- Lead certification & ISO 14001

06



# CAPEX UPDATE

- Capex incurred in FY 2021-22 : INR 151.80 Crs
- Capex planned for FY 2022-23 : INR 150.00 Crs



# AWARDS & RECOGNITION

## “India Medical Device Leader of the Year 2021” by Government of India



"Export Excellence Award" by PLEXCONCIL as the largest exporter of disposable medical devices



Export Excellence Award 2020-21  
Presented at 68th Annual General Meeting,  
Faridabad Industries Association.



# Thank You

## Poly Medicure Limited

Registered Office:

232 B, 3<sup>rd</sup> Floor, Okhla Industrial Estate, Phase III,  
New Delhi-110020, India

Tel:- 91-11-33550700, 47317000, 26321838/99

For any general queries, Reach us at:

[info@polymedicure.com](mailto:info@polymedicure.com)

Visit: [www.polymedicure.com](http://www.polymedicure.com)

CELEBRATING

